The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease

详细信息    查看全文

• 作者：W. Schuyler Jones ; MD^a ; ^{schuyler.jones@duke.edu" class="auth_mail" title="E-mail the corresponding author} ; Matthew T. Roe ; MD ; MHS^a ; Elliott M. Antman ; MD^b ; Mark J. Pletcher ; MD ; MPH^c ; Robert A. Harrington ; MD^d ; Russell L. Rothman ; MD ; MPP^e ; William J. Oetgen ; MD ; MBA^f ; Sunil V. Rao ; MD^a ; Mitchell W. Krucoff ; MD^a ; Lesley H. Curtis ; PhD^a ; Adrian F. Hernandez ; MD ; MHS^a ; Frederick A. Masoudi ; MD ; MSPH^g
• 关键词：aspirin ; coronary artery disease ; Patient-Centered Outcomes Research Institute ; pragmatic clinical trial
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：25 October 2016
• 年：2016
• 卷：68
• 期：17
• 页码：1898-1907
• 全文大小：688 K

文摘

Large randomized clinical trials in cardiovascular disease have proliferated over the past 3 decades, with results that have influenced every aspect of cardiology practice. Despite these advances, there remains a substantial need for more high-quality evidence to inform cardiovascular clinical practice, given the increasing prevalence of cardiovascular disease around the world. Traditional clinical trials are increasingly challenging due to rising costs, increasing complexity and length, and burdensome institutional and regulatory requirements. This review will examine the current landscape of cardiovascular clinical trials in the United States, highlight recently conducted registry-based clinical trials, and discuss the potential attributes of the recently launched pragmatic clinical trial by the Patient-Centered Outcomes Research Institute’s National Patient-Centered Clinical Research Network, called the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing the Benefits and Long-term Effectiveness) trial.